microRNAs potentially contributed to the female-specific expression of Cyp2b9 in the livers of C57BL/6J mice.
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Introduction
The cytochrome P450 superfamily (CYP) is a large and diverse group of enzymes that catalyze the metabolism of drugs and carcinogens. Many studies have demonstrated that gender plays an important role in the pharmacological and toxicological responses to drugs. In humans, the expression of CYP1A2, CYP2E1, CYP3A4, CYP2A6, and CYP2B6 shows gender bias, which are risk factors for clinically relevant adverse drug reactions (Anderson, 2008) . In animal models such as mice, there are gender differences in the expression of Cyp2a5, Cyp2b9/10/13, Cyp2d9, Cyp3a41/44, etc. (Hrycay and Bandiera, 2009 ). Cyp2b9 is a testosterone 16 alpha-hydroxylase enzyme showing female-specific expression in many inbred mouse strains, including C57BL/6J (Noshiro et al., 1988) . Previous studies have identified some mechanisms involved in the sexually dimorphic expression of Cyp2b9 at the transcriptional level. Sex-dependent secretion of endogenous modulating factors, especially growth hormone, glucocorticoid hormone and sex hormones, are involved in this regulatory pathway (Jarukamjorn et al., 1999; Jarukamjorn et al., 2001; Jarukamjorn et al., 2002) .
MicroRNAs are a large family of endogenous non-coding RNAs that regulate gene expression primarily by binding to the 3'-untranslated region (3′-UTR) of target genes, resulting in suppressed translation or decreased mRNA stability. MicroRNAs may regulate a b o u t 60% of all genes in humans (Bartel, 2009) . Dicer1 is an RNase III endonuclease that is essential for the biogenesis of microRNAs, and multiple Dicer1 knockout (KO) animal models show significant down-regulation of microRNAs and
up-regulation of microRNA targeting genes in these models (Hand et al., 2009; Sekine et al., 2009 ).
Recently, it has been demonstrated that microRNAs regulate cell processes necessary for sexual differentiation (Morgan and Bale, 2012) . MiR-23a contributes to sex differences in the response to cerebral ischemia by regulating the expression of X-linked inhibitor of apoptosis (XIAP) (Siegel et al., 2011) . Sex-based differences in miR-1 may underlie the sex-based differences in Cx43 expression in cardiomyocytes in pathologic conditions (Stauffer et al., 2011) .
In this study, we used a hepatocyte-specific Dicer1 KO mouse model, bioinformatics analysis and in vitro studies to investigate the role of microRNAs in the regulation of sexually dimorphic Cyp2b9.
Materials and methods
Animals. All animal treatments were approved by the Institutional Animal Care and Use Committee of the Shanghai Institute of Materia Medica (Shanghai, China).
The hepatocyte-specific Dicer1 KO C57BL/6 mouse strain was a kind gift from
Otus, Shiga, Japan). The primers for Cyp2b9 mRNA were 5'-CCTCCACTATGGAGTCCTGC-3' (forward) and 5'-ACTTGGACTGTTGGGA GGAAGA-3' (reverse), and qRT-PCR analysis was performed using SYBR® Premix Ex Taq™ (Takara, Otus, Shiga, Japan). Cyp2b9 mRNA levels were normalized to mouse Gapdh mRNA detected by primers 5'-GGCTACACTGAGGACCAGGTT-3' (forward) and 5'-TGCTGTAGCCGTATTCATTGTC-3' (reverse).
MicroRNAs were isolated with the mirVana™ miRNA Isolation Kit (Ambion, 
Results
Effects of Dicer1 disruption on the expression of Cyp2b9 in the livers of male
and female mice. We obtained the expression profile of microRNAs and CYPs in hepatocyte-specific Dicer1 KO male mice (male-KO mice). Dicer1, miR-122 and miR-192 were significantly down-regulated in male-KO mice (supplementary Figure. 2) indicating efficient KO of Dicer1. It has been previously shown that the expression of Cyp2b9 decreased in male mice during development after birth (Hashita et al., 2008) . In our study, mRNA (Fig. 1A , B) and protein (Fig. 1C, D) levels of Cyp2b9 at
1 0 3 weeks were higher in the livers of male-KO mice compared to wild-type (WT) male mice. The expression of Cyp2b9 in WT male mice at 6 weeks was extremely low, while that of KO male mice was still high (Fig. 1A-D) . However, these phenomena
were not observed in female mice at 3 or 6 weeks (supplementary Figure. 3). et al., 2005) , and finally found 22 microRNAs expressed in liver, thus we focused on studying the roles of these 22 microRNAs in the regulation of Cyp2b9 (Table 1) .
Screening of microRNAs that
qRT-PCR results further revealed that 18 of 22 microRNAs had higher expression levels in male mice (Fig. 2) . The screening strategy was summarized in supplementary Figure 4 .
Multiple microRNAs negatively regulated the expression of Cyp2b9. We constructed a Cyp2b9 3'-UTR luciferase reporter plasmid to study the post-transcriptional regulation of microRNAs on Cyp2b9 expression. Luciferase reporter assays showed that 8 of 22 microRNAs decreased luciferase activity at the final concentration of 100nM (Fig. 3A, B) . These microRNAs also down-regulated
the protein level of Cyp2b9 (Fig. 3C ). When mutations were introduced into the putative binding sites of microRNAs (mmu-miR-139-3p, 1b-5p, 21*, 291a-5p, -297a*, 297b-3p, 467g, -667) in Cyp2b9 3'-UTR (Fig. 3A) , the inhibition of luciferase activity was partially or totally abolished (Fig. 3A, B) . MicroRNAs with mutations in their seed regions also lost the inhibition of the luciferase activity (Fig. 3D) . These results suggested that 8 microRNAs (mmu-miR-139-3p, -1b-5p, -21*, -291a-5p, -297a*, -297b-3p, -467g, and -667) inhibited Cyp2b9 expression post-transcriptionally through binding to the 3'-UTR region.
Correlation analysis of the expression of microRNAs and Cyp2b9 in male and female mice. All 8 microRNAs were found to regulate Cyp2b9 had higher expression levels in male C57BL/6J mice compared to female mice (Table 1) . We performed
Pearson's correlation tests to identify potential correlations between the protein levels of Cyp2b9 protein and the levels of microRNAs in male and female WT mice at 6
weeks. Expression of mmu-miR-139-3p, 21*, 297b-3p, 467g and 667 showed weak negative correlation with Cyp2b9 expression (Fig. 4A, C, F-H) , while the expression of mmu-miR-1b-5p, 291a-5p and 297a* demonstrated strong negative correlation with Cyp2b9 expression (Fig. 4B, D and E) . Finally, the expression of mmu-miR-490-5p, which showed no regulation of Cyp2b9 by luciferase activity assay, did not correlate with Cyp2b9 expression (Fig. 4I) . The correlation coefficients between the levels of 22 microRNAs and Cyp2b9 expression were listed in Table 2 .
Discussion
It has been previously reported that the expression of Cyp2b9 developmentally decreased after birth in male mice (Hashita et al., 2008) . post-transcriptional levels via their seed region complementary to Cyp2b9 3'-UTR.
Finally, correlation analyses showed negative correlation between the expression of microRNAs and Cyp2b9. Altogether, these data strongly suggested that microRNAs post-transcriptionally regulate the expression of Cyp2b9 and participate in the gender differences of Cyp2b9 expression.
Our work suggested that some male-predominant microRNAs may participate in the negative regulation of Cyp2b9 in male mice. A previous study showed that CAR knockout caused up-regulation of Cyp2b9 expression in female mice, suggesting a negative correlation between CAR and Cyp2b9 in female mice (Mota et al., 2010) . In contrast, Cyp2b9 was down-regulated in 6-week-old Dicer1 KO female mice ( Supplementary Fig.3 ), which also showed a great increase of CAR (data not shown).
Here, we suggested that the down-regulation of Cyp2b9 in female mice may be due to the combination of up-regulation of CAR and the low levels of predicted microRNAs expression of CYP2B6.
Gender and individual differences in the expression of CYPs are universal phenomena that are driven by multiple mechanisms including genetic variation, transcriptional factors and post-transcriptional regulation (Hrycay and Bandiera, 2009 ). Sex differences in the expression of CYPs lead to sex differences in the pharmacokinetics and pharmacodynamics of many drugs; this is a primary cause of sex-related pharmacokinetics and side effects (Tanaka, 1999) . Between 6 to 7% of new drug applications with sex analyses show at least a 40% differential in pharmacokinetics between men and women (Anderson, 2005) . In this study, we demonstrated a microRNA-directed post-transcriptional regulatory mechanism that may participate in sex-biased expression of CYPs. Our results suggest a novel potential mechanism for sex-based differences in the pharmacokinetics and pharmacodynamics of drugs, and indicate that microRNAs may be important factors in sex-biased drug administration. (Table 1) were screened in a luciferase reporter system containing the Cyp2b9 3'-UTR (wild type, WT). 6 luciferase reporters containing mutant Cyp2b9 3'-UTR (mt1-mt6) were used to examine the effects of 8 microRNAs. Table 2 . 
